Watch our Member Showcase video here https://bit.ly/3HZGpJI
No data available
Switzerland is one of the strongest biotech / pharma countries in Europe with global pharma, mature biotech and innovative start-ups, supported by world class research. The Embassy of Switzerland facilitates contacts to Swiss clusters for anyone interested in business or research partnerships.
Emberion develops and produces graphene photonics and electronics that will revolutionise infrared photodetectors and thermal sensors in applications ranging from hyperspectral and thermal imaging to night vision and X-ray detection.
The mission of EMBL-EBI is to: provide freely available data and bioinformatics services to all facets of the scientific community in ways that promote scientific progress; contribute to the advancement of biology through basic investigator-driven research in bioinformatics; provide advanced bioinformatics training to scientists at all levels; and help disseminate cutting-edge technologies to industry. . The research and service activities of EMBL-EBI span the entire spectrum of life science and remain at the cutting edge of the computational sciences. All our major data resources are the products of international collaborations. We work with other data providers to ensure that our data repositories, and those of our collaborators, are comprehensive and up to date. We also actively participate in international efforts to develop data standards.. . The EMBL-EBI Industry Programme engages our industrial users with the latest bioinformatics research, service development, standards activities, pre-competitive opportunities and training https://www.ebi.ac.uk/industry.
Empyrean Therapeutics is focused on developing next generation off-the-shelf cell therapies to enable global and affordable cures for cancer and rare disease. We are building unique technologies, cellular assets and engineering processes which combine to deliver a powerful platform for rapidly manufacturing cellular drugs with novel disease fighting properties. . . Headquartered at the Babraham Research Campus, south of Cambridge, and working with leading clinical partners and academic experts, we are combining world class skills in gene editing with expertise in stem cell programming and precise genetic control to unlock the true potential of designer cellular medicines.
No data available
Immunotherapeutics company targeting a new class of tumour specific antigens
Ernst & Young is also a global leader in professional services with some 114,000 people based in 140 countries. Around the world the firm is committed to pursuing the highest levels of integrity, quality, and professionalism in delivering a broad inventory of services to our clients. Our services fall under three broad headings: Assurance and Advisory Business Services (AABS), Transaction Advisory Services (TAS) and Taxation Services. Our 'account-centric' organisational model recognises that many client issues are best addressed by a number of our service lines working together.. Ernst & Young UK comprises approximately 470 partners and 8000 staff. In 2006 UK fee income increased by 20% to £1.13bn whilst staff numbers excluding partners increased by 8% to 7,902. We provided services to 84 of the FTSE 100 companies and 93% of our clients indicated they were satisfied or very satisfied with our service. For the second year running, we qualified for the Per Cent Standard, meaning that we gave more than 1% of our notional pre-tax profits to charity and we ranked 61st in the Business in the Community's Environment Index.. . COMMITMENT TO BIOTECHNOLOGY. For the past 20 years, Ernst &Young has been a leading professional services firm serving the biotechnology industry, thanks to our extensive global network of experienced professionals and our industry-leading annual publication, Beyond Borders: The Global Biotechnology Report.. Now recognised as the industry bible, Ernst & Young's global biotechnology report, Beyond Borders, provides an overview of the latest developments in the global biotechnology sector. Our report demonstrates that on the cusp of its 30th birthday, the biotech industry is maturing rapidly, with solid financial performance and a substantial track record of bringing new products to market. The contents and themes of this report derive from substantial research by our Global Biotechnology Center, and more importantly, from our leading position serving prominent biotechnology companies around the world.. The life sciences industry is widely acknowledged as one of the leading industries in the future global economy, Ernst & Young has helped shape the global life sciences industry since its inception, advising more of its leading companies than any other professional service firm. We advise one third of life sciences companies globally, have a global network of life sciences specialists in 17 European countries, and boast the UK's largest dedicated life sciences team which our Cambridge office forms part of.. We are reporting accountants to companies in respect of their IPOs on AIM, the London Stock Exchange, and NASDAQ, and are experts in providing tax planning advice for companies seeking IPOs including share option planning.. . CONTACTS:. Julian Jenkins (Audit Partner). 01223 557073. Cathy Taylor (Tax Partner). 01223 557090. Simon Gillings (Transaction Support). 01223 557071
Essen BioScience is a world leader in the field of innovative cell-based assays, reagents, instrumentation and custom services for discovery research. Our specialities include phenotypic 'live content' kinetic imaging assays based around IncuCyte Zoom (e.g. angiogenesis, neurite outgrowth, cell migration/invasion, apoptosis etc.) and high throughput automated electrophysiology for ion channel drug discovery and safety (e.g. hERG assays). Our live content imaging solution has been adopted by laboratories across all 10 of the world’s top pharmaceutical companies as well as more than 150 leading biotechnology and academic research institutions.